Novartis AG (NVS)
NYSE: NVS · IEX Real-Time Price · USD
106.44
-0.10 (-0.09%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Novartis AG Revenue
Novartis AG had revenue of $49.92B in the twelve months ending March 31, 2024, with 8.81% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $12.12B with 9.71% year-over-year growth. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
$49.92B
Revenue Growth
+8.81%
P/S Ratio
4.17
Revenue / Employee
$656,402
Employees
76,057
Market Cap
208.25B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
Dec 31, 2005 | 29.75B | 2.48B | 9.08% |
Dec 31, 2004 | 27.28B | 2.35B | 9.41% |
Dec 31, 2003 | 24.93B | 4.05B | 19.41% |
Dec 31, 2002 | 20.88B | 2.12B | 11.27% |
Dec 31, 2001 | 18.76B | -3.07B | -14.06% |
Dec 31, 2000 | 21.83B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
Pfizer | 55.09B |
AbbVie | 54.40B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
Amgen | 29.53B |
NVS News
- 19 days ago - Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment - GlobeNewsWire
- 26 days ago - Novartis and others face Italy antitrust probe over eye drug - Reuters
- 4 weeks ago - Novartis leukemia drug more effective than older treatments in trial - Reuters
- 4 weeks ago - Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML - GlobeNewsWire
- 4 weeks ago - Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria - GlobeNewsWire
- 5 weeks ago - Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio - GlobeNewsWire
- 5 weeks ago - Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - PRNewsWire
- 5 weeks ago - This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A - CNBC